Renaldee has developed a highly effective, affordable, and pharmacologically safe, herbal active vitamin D (AVD) supplement to facilitate the treatment of chronic kidney disease (CKD). CKD is a progressive damage or loss of kidney function that affects >10% of the general population worldwide. In Europe, 50-100 million people suffer from CKD, and predictions suggest that it will become the fifth leading cause of death globally by 2040. CKD patients have exceptionally high rates of vitamin D deficiency (VDD) which is caused by the reduced activity of the kidney to synthesis Calcitriol, the active form of vitamin D. Existing synthetic Calcitriol supplements with narrow therapeutic index have reduced pharmacological tolerance to treat patients with CKD. There is therefore an unmet medical need to develop pharmacokinetically favourable, AVD supplement with an enhanced safety profile to support the treatment of CKD at all stages and prevent further complications. Renaldee’s herbal origin of Calcitriol with favourable pharmacokinetic properties will supplement the body with the essential form of VD that results from the decrease in its own production. This enables the body to function normally in the many functions in which VD plays a role, so that no subsequent damage occurs. This will improve treatment outcome and enhance the physical and mental well-being of CKD patients. The favourable pharmacokinetic properties of Renaldee’s AVD compared to synthetic vitamin D derivatives have been extensively demonstrated in animal models and in human population. The proposed compound will support the treatment of CKD and support bone health in patients with CKD & mineral bone disorder. This will massively decrease the financial and healthcare burden driven by CKD worldwide.

Wind energy is one of the fastest growing sectors in the world's energy markets. According to the EWEA, the European wind market it is expected to grow consistently at a compound annual growth rate of 9.8%. As annual blade failures are estimated at around 3,800 with poor maintenance the most common cause of accidents, ensuring the integrity of blades is a key issue with respect to the business, safety and the environment. The overall problem envisaged is the lack of effective condition monitoring systems for the blades, representing a business opportunity for the project’s partners Hence, the Project aims to commercialize a novel solution, BladeSave, marketed as a fusion between a Fibre Optic Structural Health Monitoring System providing multi-sensing capability and a management software incorporating risk based inspection data analysis and offering a comprehensive solution for blade monitoring, repair and management. Based on existing technologies developed by the partners at TRL6, BladeSave will assist WFOs in satisfying newly imposed regulations by the European Agency for Safety and Health at Work (amendments to EN 50308) and benefit European ISPs in the CM services market, giving them a competitive edge over global rivals. Our product market target consists predominantly of the WTFs installed before 2011 (currently around 71,620 in Europe) as old wind turbines have an average annual maintenance cost larger than newer models, are not covered by warranties and offer a bigger risk of catastrophic failures. The project brings together five experienced companies with a unique set of skills and expertise in the wind industry. BladeSave will have an impact on both European and foreign markets, and over the five year sales projection, we forecast a total cumulative gross profits of at least €48 million, a return of EU investment of 23:1 and the creation of about 380 jobs within consortium and associated companies which are part of the supply chain.

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.